viewTiziana Life Sciences PLC

Tiziana Life Sciences shares surge 50% after unveils inhaler design for rapid delivery of its coronavirus treatment

The group has submitted a provisional patent application for the investigational new technology, which could also be used to transport other similar treatments rapidly to the affected areas

Tiziana Life Sciences -

Shares in Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) shot up 113% after it said it had developed a handheld inhaler that will allow the rapid delivery of TZLS-501, its drug to treat inflammation of the lung caused by the coronavirus (COVID-19).

“The technology, we think, provides immediate relief thanks to the delivery speed,” said chairman Gabriele Cerrone in a statement.

It has submitted a provisional patent application for the investigational new technology, which could also be used to transport other similar treatments rapidly to the affected areas.

Currently, doctors administer life-saving drugs intravenously.

Tiziana is at the forefront of the fight against the COVID-19 infections with its an anti-interleukin-6 receptor (anti-IL6R) monoclonal antibodies. They target two proteins - interleukin-6 and tumour necrosis factor-alpha - that cause the lung inflammation seen in severe cases of the kind that hospitalised UK prime minister Boris Johnson.

However, its anti-IL6 antibodies differ from those currently on the market in being fully human rather than humanised, which means they are derived from mice.

Treatments such as TZLS-501 will be important in the fight against coronavirus as it expected that even if a vaccine is discovered and rolled out, millions may opt against having the inoculation. And, because of the way TZLS-501 works, it is likely to be effective if new strains emerge.

“The drug works not by treating the virus but attacking inflammation in the lungs - it is attacking the two proteins causing this inflammation. As such, the chances that we will work against another future strain are very high,” Tiziana chairman Cerrone told Proactive.

On-the-ground testing in China has revealed anti-IL6R mAbs, currently approved for rheumatoid arthritis, has a role to play in treating patients.

So, the country’s National Health Commission has recommended the use of Roche blockbuster, Actemra, for patients infected with COVID-19 with serious lung damage and elevated IL-6 levels.

Sanofi’s Kevzara, another FDA-approved anti-IL-6 receptor arthritis therapy, could be used in this setting.

Tiziana, meanwhile, is keen to get the drug to patients as soon as it is practicable - and the regulatory timeline will allow. It will administer TZLS-501 using its proprietary formulation technology.

It said the features of its drug candidate should provide it with “distinct advantages” other anti-IL-6R mAbs such as Actemra and Kevzara in treating severely affected COVID-19 patients.

The aforementioned advantages are TZLS-501’s dual mechanism of action to inhibit signalling by the membrane-bound and soluble IL-6 receptors along with the rapid depletion of circulating IL-6 cytokine, a major cause of lung damage.

In early trade, the shares were up 42.5p at 80 each, valuing Tiziana at £123mln.

---updates share price and additional comment---

Quick facts: Tiziana Life Sciences PLC

Price: 82.5 GBX

Market: AIM
Market Cap: £160.56 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...


Tiziana Life Sciences to trial 'first ever take-home capsules' of Foralumab...

Tiziana Life Sciences PLC's (LON:TILS) (NASDAQ:TLSA) CEO Kunwar Shailubhai speaks to Proactive's Andrew Scott following the news they're collaborating with Parexel Biotech to conduct a global Phase 1b/2 trial with enteric-coated capsules of formulated Foralumab as a therapy for patients with...

3 weeks, 2 days ago

3 min read